Vinay Prasad, an official for the Food and Drug Administration, is reportedly stepping down, which is welcome news for ...

Josh Brown, CEO of Ritholtz Wealth Management, made a pointed claim on CNBC’s Halftime Report this week about large-cap ...

The stock looks like a great pick to help turn investors into multimillionaires, given enough time. Everyone should save ...

Looking to invest in biotech stocks? Learn what they are, explore top options, and find out how to get started in this fast-growing, exciting industry.

The market seems to be falling heavily out of love with the AI stocks, and for good reason: CapEx is rising at a staggering ...

Biotech investors have rarely united so strongly against a Food and Drug Administration official as they did against Vinay Prasad, who led the FDA's vaccines and related biological products division a ...

As of the end of 2025, Evommune had $216.7 million in cash and equivalents on its books, up from $72 million at the end of 2024. The company said that sum, along with proceeds from a recent private ...

We're also trying to make sure we look back at some of the trades that are still alive so we can keep you posted. We wrote ...

Shares of certain biotech firms were rising ahead of market open on Monday on news of the departure of the FDA’s vaccine chief, Dr. Vinay Prasad. Prasad, the head of the FDA’s division of vaccines and ...

The Company’s presence at ATTD follows compelling clinical performance data from its latest CGM technology developments, which formed the basis for Trinity Biotech’s decision to advance the program ...

Clinical trial results support progression of CGM+ toward regulatory submissions and scaled commercialization - Anticipating initiation of ...